Rifampin Capsules Recalled Due to Manufacturing Control Deviation
Lupin Pharmaceuticals is recalling Rifampin 150 mg capsules (lot #A200170) nationwide due to a Current Good Manufacturing Practice deviation with an out-of-specification impurity detected during manufacturing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for a manufacturing quality control deviation with no reported illnesses or injuries. The out-of-specification impurity was detected through routine testing, making this a precautionary recall.
Plain-English summary
Lupin Pharmaceuticals Inc. is recalling Rifampin Capsules, USP, 150 mg (lot #A200170, expiration December 2023) distributed nationwide. The recall involves 7,872 bottles of 30-count HDPE bottles (NDC 68180-658-06).
The recall was initiated due to a Current Good Manufacturing Practice (CGMP) deviation discovered during manufacturing. Testing identified an out-of-specification result for 1-Methyl-4-Nitroso Piperazine (MNP), an impurity that exceeded acceptable limits.
Rifampin is a prescription antibiotic used to treat tuberculosis and other serious infections. Patients currently taking this medication should consult their healthcare provider before making any changes. Those with a bottle from lot #A200170 should contact their pharmacy or healthcare provider for guidance on the recalled medication.
The recalled product
- Product
- RIFAMPIN (RIFAMPIN)
- Brand
- RIFAMPIN
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Antibiotic / Prescription
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #A200170
- exp. date December 2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · RIFAMPIN
- HighRifampin Antibiotic Capsules Recalled for Subpotency and Failed Specifications
FDA (Drugs) · 2024-02-07
- HighRifampin Capsules Recalled Due to Failed Impurity and Degradation Specification
FDA (Drugs) · 2024-02-07
- HighAntibiotic Rifampin Capsules Recalled for Subpotency and Quality Failures
FDA (Drugs) · 2024-02-07
- HighPrescription Rifampin Capsules Recalled Due to Failed Quality Specifications
FDA (Drugs) · 2023-01-25
- HighPrescription Rifampin Capsules Recalled for Failed Impurity Specifications
FDA (Drugs) · 2023-01-18
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateGanirelix acetate injection recalled after failing an impurity specification
FDA (Drugs) · 2025-12-17
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09